Brown Advisory Inc. Sells 12,506 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Brown Advisory Inc. decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 84.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,219 shares of the medical research company's stock after selling 12,506 shares during the quarter. Brown Advisory Inc.'s holdings in Charles River Laboratories International were worth $334,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Cibc World Markets Corp increased its holdings in shares of Charles River Laboratories International by 16.1% during the fourth quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company's stock valued at $1,493,000 after acquiring an additional 1,124 shares in the last quarter. Royal London Asset Management Ltd. grew its stake in Charles River Laboratories International by 6.4% in the 4th quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company's stock valued at $3,032,000 after purchasing an additional 991 shares during the period. Quantbot Technologies LP grew its stake in Charles River Laboratories International by 13.8% in the 4th quarter. Quantbot Technologies LP now owns 9,300 shares of the medical research company's stock valued at $1,717,000 after purchasing an additional 1,131 shares during the period. American Century Companies Inc. grew its stake in Charles River Laboratories International by 5.6% in the 4th quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company's stock valued at $551,000 after purchasing an additional 157 shares during the period. Finally, Sei Investments Co. lifted its position in shares of Charles River Laboratories International by 6.1% during the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company's stock valued at $124,394,000 after buying an additional 38,827 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Down 1.4%

Shares of CRL stock traded down $2.15 during mid-day trading on Friday, hitting $154.55. The company's stock had a trading volume of 493,642 shares, compared to its average volume of 1,035,730. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The business has a 50-day moving average price of $147.42 and a 200 day moving average price of $150.81. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of -237.77, a PEG ratio of 5.31 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the company posted $2.27 earnings per share. Charles River Laboratories International's revenue was down 2.7% compared to the same quarter last year. Research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the topic of several recent analyst reports. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Barclays increased their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Robert W. Baird raised their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $174.54.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).